Greg Zante - Jan 3, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Financial Officer
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Jan 3, 2024
Transactions value $
-$1,380,965
Form type
4
Date filed
1/4/2024, 09:35 PM
Previous filing
Apr 18, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +28.3K +17.67% $0.00 189K Jan 3, 2024 Direct F1, F2
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$317K -18.2K -9.66% $17.40 170K Jan 3, 2024 Direct F3
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +70K +41.06% $0.00 240K Jan 3, 2024 Direct F4
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$537K -30.9K -12.84% $17.40 210K Jan 3, 2024 Direct F5
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$258K -13.9K -6.62% $18.58 196K Jan 4, 2024 Direct F5
transaction VKTX Common Stock, par value $0.00001 per share Sale -$269K -15K -7.66% $17.90 181K Jan 4, 2024 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Award $0 +155K $0.00 155K Jan 3, 2024 Common Stock 155K $17.40 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal.
F2 Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
F4 Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
F5 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.
F7 25% of the shares subject to the option will vest on each anniversary of the grant date.